Skip to main content

Advertisement

SpringerLink
Log in

Assessment of the circulating klotho protein in lung cancer patients

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

The anti-aging factor, klotho has been identified as a tumor suppressor in various human cancers, including lung cancer. In vitro studies provided evidence that klotho expression influences the characteristics of lung cancer cells, however, in vivo results are lacking. The aim of our study was to evaluate whether circulating klotho protein might serve as a potential biomarker of lung cancer. Blood samples were taken from 45 newly diagnosed lung cancer patients (31 NSCLC, 14 SCLC) and 43 control subjects. Plasma klotho concentration was measured using ELISA. No difference in plasma klotho values was detected between patients and control subjects (366.3 (257.9–486.8) vs. 383.5 (304.6–489.7) pg/ml respectively (median (IQR)); p > 0.05). Plasma klotho levels in patients with distant metastasis did not differ from less advanced stage disease (354.2 (306.9–433.3 vs. 328.5 (242.5–419.7) pg/ml, p > 0.05). In contrast, analyzed with one-way ANOVA, significant difference (p = 0.04) was found between the examined histological types of lung cancer: adenocarcinoma (353 (329.4–438.5) pg/ml), squamous cell carcinoma (308 (209.6–348.1) pg/ml) and small cell lung cancer (388.8 (289.9–495.4) pg/ml). However, Tukey’s post hoc test did not reveal significant difference between any pairs of histological groups. There was no difference between any histological subtype and health either. Our results suggest that circulating klotho protein cannot be considered as a biomarker for lung cancer. Further studies are warranted in order to examine the relationship between klotho expression in lung tissue and circulating levels of the protein, and to explore its mechanism of action in lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chang B, Kim J, Jeong D, Jeong Y, Jeon S, Jung SI et al (2012) Klotho inhibits the capacity of cell migration and invasion in cervical cancer. Oncol Rep 28:1022–1028

    Article  CAS  Google Scholar 

  2. Yan Y, Wang Y, Xiong Y, Lin X, Zhou P, Chen Z (2017) Reduced Klotho expression contributes to poor survival rates in human patients with ovarian cancer, and overexpression of Klotho inhibits the progression of ovarian cancer partly via the inhibition of systemic inflammation nude mice. Mol Med Rep 15:1777–1785

    Article  CAS  Google Scholar 

  3. Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H et al (2008) Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 27:7094–7105

    Article  CAS  Google Scholar 

  4. Rubinek T, Wolf I (2016) The role of alpha-klotho as a universal tumor supressor. Vitam Horm 101:197–214

    Article  CAS  Google Scholar 

  5. Zhou X, Wang X (2015) Klotho: a novel biomarker for cancer. J Cancer Res Clin Oncol 141:961–969

    Article  CAS  Google Scholar 

  6. Kuro-o M (2010) Klotho. Eur J Physiol 459:333–343

    Article  CAS  Google Scholar 

  7. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P et al (2005) Suppression of aging in mice by the Hormone Klotho. Science 5742:1829–1833

    Article  Google Scholar 

  8. Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J et al (2007) Augmented Wnt signaling in a mammalian model of accelerated aging. Science 317:803–806

    Article  CAS  Google Scholar 

  9. Velcheti V, Ramaswamy G (2006) Insulin-like growth factor and lung cancer. J Thorac Oncol 1:607–610

    PubMed  Google Scholar 

  10. He B, Barg RN, You L, Xu Z, Reguart N, Mikami I et al (2005) Wnt signaling in stem cells and non-small-cell lung cancer. Clin Lung Cancer 7:54–60

    Article  CAS  Google Scholar 

  11. Fidler MJ, Shersher DD, Borgia JA, Bonomi P (2012) Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol 4:51–60

    Article  CAS  Google Scholar 

  12. Yang J, Chen J, He J, Li J, Shi J, Cho WC et al (2016) Wnt signaling as potential therapeutic target in lung cancer. Expert Opin Ther Targets 20:999–1015

    Article  CAS  Google Scholar 

  13. Chen B, Ma X, Liu S, Zhao W, Wu J (2012) Inhibition of lung cancer cells growth, motility and induction of apoptosis by Klotho, a novel secreted Wnt antagonist in a dose-dependent manner. Cancer Biol Ther 13:1221–1228

    Article  CAS  Google Scholar 

  14. Usuda J, Ichinose S, Ishizumi T, Ohtani K, Inoue T, Saji H et al (2011) Klotho predicts good clinical outcome in patients with limited-disease small cell lung cancer who received surgery. Lung Cancer 74:332–337

    Article  Google Scholar 

  15. Usuda J, Ichinose S, Ishizumi T, Ohtani K, Inoue T, Saji H et al (2011) Klotho is a novel biomarker for good survival in resected large cell neuroendocrine carcinoma of the lung. Lung Cancer 72:355–359

    Article  Google Scholar 

  16. Chen B, Wang X, Zhao W, Wu J (2010) Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549. J Exp Clin Cancer Res 29:99

    Article  Google Scholar 

  17. Chen T, Ren H, Thakur A, Yang T, Li Y, Zhang S et al (2016) Decreased level of klotho contributes to drug resistance in lung cancer cells: involving in klotho-mediated cell autophagy. DNA Cell Biol 35:751–757

    Article  CAS  Google Scholar 

  18. Wang Y, Chen L, Huang G, He D, He J, Xu W et al (2013) Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway. PLoS One 8:e57391

    Article  CAS  Google Scholar 

  19. Tang X, Fan Z, Huang S (2013) Can soluble klotho protein be a potential tumor biomarker? Am J Clin Pathol 139:259–262

    Article  Google Scholar 

  20. Gigante M, Lucarelli G, Divella C, Netti GS, Pontrelli P, Cafiero C et al (2015) Soluble serum αklotho is a potential predictive marker of disease progression in clear cell renal cell carcinoma. Medicine 94:e1917

    Article  CAS  Google Scholar 

  21. Pedersen L, Pedersen SM, Brasen CL, Rasmussen LM (2013) Soluble serum klotho levels in healthy subjects. Comparison of two different immunoassays. Clin Biochem 46:1079–1083

    Article  CAS  Google Scholar 

  22. Pako J, Barta I, Balogh Z, Kerti M, Drozdovszky O, Bikov A et al (2017) Assessment of the anti-aging klotho protein in patients with COPD undergoing pulmonary rehabilitation. COPD 14:176–180

    Article  Google Scholar 

  23. Patel MS, Donaldson AV, Lewis A, Natanek SA, Lee JY, Andersson YM et al (2016) Klotho and smoking – An interplay influencing the skeletal muscle functions deficits that occur in COPD. Respir Med 113:50–56

    Article  CAS  Google Scholar 

  24. Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y et al (2010) Establishment of sandwich ELISA for soluble alpha-klotho measurement: Age-dependent change of soluble alpha-klotho levels in healthy subjects. Biochem Biophys Res Commun 398:513–518

    Article  CAS  Google Scholar 

  25. Rubinek T, Shulman M, Israeli S, Bose S, Avraham A, Zundelevich A et al (2012) Epigenetic silencing of the tumor suppressor klotho in human breast cancer. Breast Cancer Res Treat 133:649–657

    Article  CAS  Google Scholar 

  26. Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q et al (2013) Epigenetic silencing of klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol 44:795–801

    Article  CAS  Google Scholar 

  27. Usugi T, Ohno T, Ohyama Y, Uchiyama T, Saito Y, Matsumura Y et al (2000) Decreased insulin production and increased insulin sensitivity in the klotho mutant mouse, a novel animal model for human aging. Metabolism 49:1118–1123

    Article  Google Scholar 

  28. Neidert MC, Sze L, Zwimpfer C, Sarnthein J, Seifert B, Frei K et al (2013) Soluble α-klotho: a novel serum biomarker for the activity of GH-producing pituitary adenomas. Eur J Endocrinol 168:575–583

    Article  CAS  Google Scholar 

  29. Sze L, Bernays RL, Zwimpfer C, Wiesli P, Brändle M, Schmid C (2012) Excessively high soluble Klotho in patients with acromegaly. J Intern Med 272:93–97

    Article  CAS  Google Scholar 

  30. Kohler S, Tschopp O, Sze L, Neidert M, Bernays RL, Spanaus KS et al (2013) Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery. Gen Comp Endocrinol 188:282–287

    Article  CAS  Google Scholar 

  31. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X (1999) Plasma levels of insulin-like growth factor-1 and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151–156

    Article  CAS  Google Scholar 

  32. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M (2002) Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-carotene and retinol efficacy trial cohort. Cancer Epidemiol Biomarkers Prev 11:1413–1418

    CAS  PubMed  Google Scholar 

  33. Zhang M, Li X, Zhang X, Yang Y, Feng Z, Liu X (2014) Association of serum hemoglobin A1c, C-peptide and insulin-like growth factor-1 levels with the occurrence and development of lung cancer. Mol Clin Oncol 4:506–508

    Article  Google Scholar 

  34. Tas F, Bilgin E, Tastekin D, Erturk K, Duranyildiz D (2016) Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer. Biomed Rep 4:609–614

    Article  CAS  Google Scholar 

  35. Minuto F, Del Monte P, Barreca A, Alama A, Cariola G, Giordano G (1988) Evidence for autocrine mitogenic stimulation by somatomedin-C/insuline-like growth factor I on an established human lung cancer cell line. Cancer Res 48:3716–3719

    CAS  PubMed  Google Scholar 

  36. Toshifumi S, Takeshita Y, Murohara T, Sasaki K, Egami K, Shintani S et al (2004) Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation 110:1148–1155

    Article  Google Scholar 

  37. Fukino K, Suzuki T, Saito Y, Shindo T, Amaki T, Kurabayashi M et al (2002) Regulation of angiogenesis by the aging suppressor gene klotho. Biochem Biophys Res Commun 293:332–337

    Article  CAS  Google Scholar 

  38. Pan JY, Sun CC, Li SJ, Huang J, Li DJ (2015) Role of miR-10b in non-small cell lung cancer (NSCLC) cells by targeting klotho. Cancer Cell Microenviron 2:e936

    Google Scholar 

  39. Qi HW, Shen Z, Fan LH (2011) Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line. Exp Ther Med 2:1091e1095

    Article  Google Scholar 

Download references

Acknowledgements

The authors are thankful to Timea Barna and Sandy Bartok for blood sample collection and Maria Mikoss for laboratory assistance.

Funding

This work was supported by the research grant provided by the Hungarian Respiratory Society to Judit Pako and by the Bolyai János Scholarship provided by the Hungarian Academy of Sciences to Andras Bikov.

Author information

Authors and Affiliations

  1. National Koranyi Institute of Pulmonology, Piheno ut 1, Budapest, 1121, Hungary

    Judit Pako, Imre Barta, Anna Kerpel-Fronius, Balazs Antus & Ildiko Horvath

  2. Department of Pulmonology, Semmelweis University, Dios arok utca 1/c, Budapest, 1125, Hungary

    Andras Bikov, Rita Puskas & Gabriella Galffy

  3. Saitama Medical University Medical Center, 1981 Kamoda, Kawagoe-shi, Saitama, Japan

    Hideyo Matsueda

Authors
  1. Judit Pako
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andras Bikov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Imre Barta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideyo Matsueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rita Puskas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gabriella Galffy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anna Kerpel-Fronius
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Balazs Antus
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ildiko Horvath
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Judit Pako.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pako, J., Bikov, A., Barta, I. et al. Assessment of the circulating klotho protein in lung cancer patients. Pathol. Oncol. Res. 26, 233–238 (2020). https://doi.org/10.1007/s12253-018-0441-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-018-0441-5

Keywords

Search

Navigation